Quick Read
-
Eli Lilly (LLY) earns a BUY rating with a $1,220 price target, backed by 47% revenue growth and four straight EPS beats.
-
Novo Nordisk (NVO) trades at a forward P/E of 14 with just 2% revenue growth, making Lilly’s premium valuation at 24x look justified.
-
Retatrutide’s BLA submission planned for Q1 2027 is the bull catalyst that could drive shares to $1,382, while pricing declines are the primary risk.
-
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn’t make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.
Eli Lilly has joined the trillion-dollar club, and the question every long-only investor is asking is whether the run has more room. My take: yes, but the easy money is behind us.
Eli Lilly (NYSE:LLY) trades at $1,123.98 with a market cap of $1.002 trillion. Our 24/7 Wall St. price target for Lilly is $1,220.42 over the next 12 months, implying 8.58% upside. The recommendation is buy with high confidence at 90%.
24/7 Wall St. Price Target Summary
How Lilly Got to a Trillion, and Where Shares Sit Now
Shares are up 50.72% over the past year but down 8.61% over the past month as investors digest a scorching run. LLY sits below its 52-week high of $1,292.65 and well above the low of $707.59.
The engine remains Mounjaro and Zepbound: Q2 2026 revenue reached $22.974 billion, up 47.67% year over year, with EPS of $8.38 beating consensus by 27.27%. Mounjaro alone posted $9.94 billion (+91% YoY), and management raised full-year revenue guidance to $85 billion to $87 billion.
Free Report, Just Released
Why Didn’t LLY Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And LLY didn’t make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Enter Your Email and See the Ten →
Bull Case for $1,381 and Higher
The bull path takes LLY to $1,381.62, a 22.92% gain. The catalysts are real. Retatrutide, Lilly’s triple-agonist, delivered what management called “unprecedented efficacy” across three Phase 3 trials, with a BLA submission planned for Q1 2027.
